AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00973167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration treatment
Description: Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
Study NCT00090259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Description: 50-mg losartan oral tablet
Study NCT00090259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Description: 100-mg losartan oral tablet + 50-mg losartan oral tablet
Study NCT03781817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketamine
Description: Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
Study NCT03781817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
Study NCT00939367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets 10 mg
Study NCT00939367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg
Study NCT03361839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy for genetic study of endometrial receptivity
Study NCT03361839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy for genetic study of endometrial receptivity
Study NCT01800500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Purchase ST products using a fixed rate of product prices
Study NCT01800500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Purchase ST products using escalating product prices
Study NCT01800500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01800500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01800500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01800500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ecigarettes
Description: Purchase ST products using escalating product prices nicotine replacement therapy
Study NCT01800500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ecigarettes
Description: Purchase ST products using a fixed rate of product prices nicotine replacement therapy
Study NCT02423564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Digesta Lac
Study NCT02423564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01966185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tutor function on
Description: The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
Study NCT04125498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic treatment
Description: Manual treatment that aims to release myofascial tensions
Study NCT04125498 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo treatment
Description: Similar to OMT without pressure
Study NCT04125498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo treatment
Description: Similar to OMT without pressure
Study NCT04125498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-massage
Description: Women will be instructed to perform self-massage at home once a day for 5 minutes.
Study NCT00474994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT02384980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES (Gait MyoElectric Stimulator)
Description: Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
Study NCT03755960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
Study NCT03802279 — intervention group
Intervention type: OTHER
Intervention: Effort test
Description: Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated.
Study NCT01929226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ETI-204
Study NCT03231007 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
Study NCT02611726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study NCT00670904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-delivered group program for smoking cessation
Description: Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
Study NCT00670904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brief standard care session for smoking cessation delivered over the telephone
Description: Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
Study NCT01459445 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin, Ethinylestradiol 30µg-Drospirenone
Description: Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
Study NCT04395807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet CPAP
Description: Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
Study NCT04395807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
Study NCT02438423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02283723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY Intervention
Description: The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
Study NCT02283723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
Study NCT02454023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable sleep monitor (ApneaLink Air)
Description: Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
Study NCT02454023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Study NCT01227980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pexacerfont
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study NCT03755960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine care
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
Study NCT03755960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
Study NCT01164280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse Rate Change
Description: Different pulse rate settings of the implantable neurostimulator
Study NCT01227980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study NCT04318769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFFIRM
Description: AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
Study NCT01412164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIREHAWK biodegradable polymer rapamycin-eluting stent
Description: DES PCI for CAD
Study NCT00567450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 30ml of a mixture of ropivacaïne 0.75%
Study NCT00567450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plus mepivacaine
Description: 30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
Study NCT02742831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan.
Study NCT02742831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
Study NCT00771199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Therapeutic System (TTS)-Fentanyl
Description: Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
Study NCT01922713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: white maize and a corn oil capsule
Description: \~ 0 ug RAE/d
Study NCT01922713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orange maize and a corn oil capsule
Description: \~600 ug RAE/d
Study NCT01922713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white maize and a vitamin A capsule
Description: 600 ug RAE/d
Study NCT01218581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
Study NCT00165672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABEPRAZOLE SODIUM
Description: rabeprazole sodium 5 mg: once daily orally for 4 weeks
Study NCT00165672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABEPRAZOLE SODIUM
Description: rabeprazole sodium 10 mg: once daily orally for 4 weeks
Study NCT00571974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL-585, ScleroPLUS laser
Description: PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
Study NCT00571974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid (Levulan KerastickTM)
Description: Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
Study NCT00571974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Diagnosis Imaging
Description: FD Image taken prior to PDL-585 usage
Study NCT00893061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study NCT00893061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally
Study NCT00893061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00893061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT01105208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin suspension (Optocef, BAYO5448 )
Description: Single dose of 500 mg / 10 mL
Study NCT01105208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin suspension (Keflex)
Description: Single dose of 500 mg / 20 mL
Study NCT00761761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril
Study NCT00761761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02953873 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus Extended Release Capsule
Description: goal trough 5 - 12ng/mL
Study NCT00851617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® IMT
Description: The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
Study NCT04632771 — intervention group
Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)
Study NCT00659451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: tablets; 50, 100 mg; od; 12 months
Study NCT00659451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: tablets; 5, 10 mg; od; 12 months
Study NCT02762929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011A
Description: HTX-011A (bupivacaine/meloxicam), via injection.
Study NCT02762929 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo via injection.
Study NCT02762929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Study NCT03802279 — intervention group
Intervention type: OTHER
Intervention: Functional tests on fibroblasts
Description: Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
Study NCT02762929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-002
Description: HTX-002, via injection.
Study NCT02953873 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: ≥500mg twice a day
Study NCT02610686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chloroquine
Description: efficacy of chloroquine for the treatment of Plasmodium vivax infections
Study NCT02556606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
Study NCT02556606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
Study NCT02556606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
Study NCT00362648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
Description: 2.0 mL oral dose of RotaTeq™. 14 week treatment period
Study NCT02556606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single 40 min infusion of MID 0.03mg/Kg
Study NCT02762929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCI, via injection.
Study NCT02762929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-009
Description: HTX-009, via injection.
Study NCT01117896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest compression on adult and pedi manikins
Description: Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
Study NCT00514670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer & quaternary ammonium wipes
Study NCT01117896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of stepstool during chest compressions
Description: In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
Study NCT01773707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA4-Ig (Abatacept)
Description: Given as 30 minute IV infusion
Study NCT01432067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adapted physical activity
Description: Physical activity advices according to a program adapted to physical status of the patient.
Study NCT01432067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic physical activities
Description: Daily physical activities based on a standard guide
Study NCT01416636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil sodium
Study NCT01416636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil sodium
Study NCT02953873 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: goal dose 5mg daily
Study NCT02953873 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Sodium
Description: ≥360mg twice a day
Study NCT03574818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab-Gemcitabine-Cisplatin
Description: * Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles.